

Ramon Yarza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5212545/publications.pdf>

Version: 2024-02-01

9
papers

400
citations

1684188

5
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

896
citing authors

#	ARTICLE	IF	CITATIONS
1	c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2015, 6, 321.	3.5	284
2	SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. <i>European Journal of Cancer</i> , 2020, 135, 242-250.	2.8	74
3	Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review. <i>Journal of Breast Cancer</i> , 2019, 22, 661.	1.9	17
4	Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 202.	8.6	14
5	Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm. <i>Clinical Lung Cancer</i> , 2020, 21, e1-e5.	2.6	8
6	Nivolumab induced immune mediated transverse myelitis in a patient with metastatic melanoma: The broad clinical spectrum of immune mediated neurologic disorders. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100076.	0.1	2
7	Oesophageal ulcer: An uncommon presentation of tuberculous lymphadenitis mimicking an oesophageal carcinoma. <i>Gastroenterology and Hepatology</i> , 2020, 43, 133-134.	0.5	1
8	PD-L1, VISTA, and CD47 expression and prognosis impact in malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 8562-8562.	1.6	0
9	Centrally determined PD-L1 among non-eligible for cisplatin-based chemotherapy recurrent/metastatic head and neck patients (R/M HNSCC pts): Pathology outcomes from the NIVOTAX trial. <i>Journal of Clinical Oncology</i> , 2022, 40, e18015-e18015.	1.6	0